Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab

This trial is testing a combination of APG-157 (an experimental oral drug derived from curcumin) and bevacizumab (a drug that blocks tumor blood vessel growth) for patients with high-grade brain tumors (glioma, grade III or IV) that have come back after prior treatment. **You may be eligible if...** - You are 19 or older (age of consent in Nebraska) - You have been diagnosed with a high-grade glioma (grade III or IV, including glioblastoma) that has progressed on bevacizumab - You have previously received radiation therapy and standard temozolomide chemotherapy - You are in reasonable health (ECOG 0–3) - Your blood counts, kidney function, and liver function are within acceptable levels **You may NOT be eligible if...** - Your cancer is not a high-grade glioma or has not previously progressed on bevacizumab - You have not recovered from side effects of your last treatment - You are pregnant or breastfeeding - You have severe organ dysfunction Talk to your doctor to see if this trial is right for you.